M. Gilbert, M. Wang, K. Aldape, R. Stupp, M. Hegi et al., Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial, Journal of Clinical Oncology, vol.31, issue.32, 2013.
DOI : 10.1200/JCO.2013.49.6968

D. Reardon, B. Neyns, M. Weller, J. Tonn, L. Nabors et al., Cilengitide: an RGD pentapeptide ??????3 and ??????5 integrin inhibitor in development for glioblastoma and other malignancies, Future Oncology, vol.7, issue.3, pp.339-354, 2011.
DOI : 10.2217/fon.11.8

M. Hegi, A. Diserens, T. Gorlia, M. Hamou, N. De-tribolet et al., Gene Silencing and Benefit from Temozolomide in Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.997-1003, 2005.
DOI : 10.1056/NEJMoa043331

W. Wick, M. Platten, C. Meisner, J. Felsberg, G. Tabatabai et al., Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial, The Lancet Oncology, vol.13, issue.7, pp.707-715, 2012.
DOI : 10.1016/S1470-2045(12)70164-X

M. Weller, R. Stupp, G. Reifenberger, A. Brandes, M. Van-den-bent et al., MGMT promoter methylation in malignant gliomas: ready for personalized medicine?, Nature Reviews Neurology, vol.113, issue.1, pp.39-51, 2010.
DOI : 10.1038/nrneurol.2009.197

D. Malley, R. Hamoudi, S. Kocialkowski, D. Pearson, V. Collins et al., A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts, Acta Neuropathologica, vol.137, issue.5, pp.651-661, 2011.
DOI : 10.1007/s00401-011-0803-5

N. Shah, B. Lin, Z. Sibenaller, T. Ryken, H. Lee et al., Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM, PLoS ONE, vol.121, issue.1, p.16146, 2011.
DOI : 10.1371/journal.pone.0016146.s005

M. Esteller, S. Hamilton, P. Burger, S. Baylin, and J. Herman, Inactivation of the DNA repair gene O6-methylguanine- DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia, Cancer Res, vol.59, pp.793-797, 1999.

I. Vlassenbroeck, S. Califice, A. Diserens, E. Migliavacca, J. Straub et al., Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma, The Journal of Molecular Diagnostics, vol.10, issue.4, pp.332-337, 2008.
DOI : 10.2353/jmoldx.2008.070169

V. Quillien, A. Lavenu, L. Karayan-tapon, C. Carpentier, M. Labussiere et al., Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g, Cancer, vol.12, issue.17, pp.4201-4211, 2012.
DOI : 10.1002/cncr.27392

S. Mulholland, D. Pearson, R. Hamoudi, D. Malley, C. Smith et al., MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations, International Journal of Cancer, vol.113, issue.5, pp.1104-1113, 2012.
DOI : 10.1002/ijc.26499

P. Heagerty and Y. Zheng, Survival Model Predictive Accuracy and ROC Curves, Biometrics, vol.9, issue.1, pp.92-105, 2005.
DOI : 10.1093/biostatistics/kxh013

DOI : 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4

L. Karayan-tapon, V. Quillien, J. Guilhot, M. Wager, G. Fromont et al., Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods, Journal of Neuro-Oncology, vol.16, issue.3, pp.311-322
DOI : 10.1007/s11060-009-0031-1

URL : https://hal.archives-ouvertes.fr/inserm-00435222

G. Reifenberger, B. Hentschel, J. Felsberg, G. Schackert, M. Simon et al., Predictive impact of MGMT promoter methylation in glioblastoma of the elderly, International Journal of Cancer, vol.28, issue.6, pp.1342-1350, 2012.
DOI : 10.1002/ijc.27385

A. Christians, C. Hartmann, A. Benner, J. Meyer, A. Von-deimling et al., Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma, PLoS ONE, vol.63, issue.3, p.33449, 2012.
DOI : 10.1371/journal.pone.0033449.t003

A. Havik, P. Brandal, H. Honne, H. Dahlback, D. Scheie et al., MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR, Journal of Translational Medicine, vol.10, issue.1, 2012.
DOI : 10.1007/s11060-008-9600-y

J. Dunn, A. Baborie, F. Alam, K. Joyce, M. Moxham et al., Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy, British Journal of Cancer, vol.33, issue.1, pp.124-131, 2009.
DOI : 10.1097/nen.0b013e31815f65fb

J. Felsberg, M. Rapp, S. Loeser, R. Fimmers, W. Stummer et al., Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients, Clinical Cancer Research, vol.15, issue.21, pp.6683-6693, 2009.
DOI : 10.1158/1078-0432.CCR-08-2801

M. Weller, J. Felsberg, C. Hartmann, H. Berger, J. Steinbach et al., Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network, Journal of Clinical Oncology, vol.27, issue.34, pp.5743-5750, 2009.
DOI : 10.1200/JCO.2009.23.0805

G. Minniti, M. Salvati, A. Arcella, F. Buttarelli, D. Elia et al., Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide, Journal of Neuro-Oncology, vol.16, issue.18, pp.311-316, 2011.
DOI : 10.1007/s11060-010-0324-4

P. Bady, D. Sciuscio, A. Diserens, J. Bloch, M. Van-den-bent et al., MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status, Acta Neuropathologica, vol.6, issue.4, pp.547-560, 2012.
DOI : 10.1007/s00401-012-1016-2